My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 956

    1.

    Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.

    Damci T, Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M, Ilkova H.

    Diabetes Care. 2004 May;27(5):1077-80.PMID: 15111524 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.

    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.

    J Clin Endocrinol Metab. 2003 Jun;88(6):2706-13.PMID: 12788877 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.

    Lee A, Patrick P, Wishart J, Horowitz M, Morley JE.

    Diabetes Obes Metab. 2002 Sep;4(5):329-35.PMID: 12190996 [PubMed - indexed for MEDLINE]Related articles

    4.

    Ethanol with a mixed meal decreases the incretin levels early postprandially and increases postprandial lipemia in type 2 diabetic patients.

    Dalgaard M, Thomsen C, Rasmussen BM, Holst JJ, Hermansen K.

    Metabolism. 2004 Jan;53(1):77-83.PMID: 14681846 [PubMed - indexed for MEDLINE]Related articles

    5.

    Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients.

    Vilsbøll T, Krarup T, Deacon CF, Madsbad S, Holst JJ.

    Diabetes. 2001 Mar;50(3):609-13.PMID: 11246881 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes.

    Thomsen C, Storm H, Holst JJ, Hermansen K.

    Am J Clin Nutr. 2003 Mar;77(3):605-11.PMID: 12600850 [PubMed - indexed for MEDLINE]Related articlesFree article

    7.

    Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

    Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.

    Diabetes Obes Metab. 2003 May;5(3):180-8.PMID: 12681025 [PubMed - indexed for MEDLINE]Related articles

    8.

    The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

    Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.

    J Clin Endocrinol Metab. 2003 Oct;88(10):4897-903.PMID: 14557471 [PubMed - indexed for MEDLINE]Related articlesFree article

    9.

    Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and cardiovascular responses to, a high-fat/carbohydrate meal in type 2 diabetes.

    O'Donovan D, Horowitz M, Russo A, Feinle-Bisset C, Murolo N, Gentilcore D, Wishart JM, Morris HA, Jones KL.

    Diabetologia. 2004 Dec;47(12):2208-14. Epub 2004 Dec 15.PMID: 15662558 [PubMed - indexed for MEDLINE]Related articles

    10.

    Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

    Toft-Nielsen MB, Madsbad S, Holst JJ.

    Diabetes Care. 1999 Jul;22(7):1137-43.PMID: 10388979 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    The role of postprandial releases of insulin and incretin hormones in meal-induced satiety--effect of obesity and weight reduction.

    Verdich C, Toubro S, Buemann B, Lysgård Madsen J, Juul Holst J, Astrup A.

    Int J Obes Relat Metab Disord. 2001 Aug;25(8):1206-14.PMID: 11477506 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions.

    Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B.

    Diabetes Care. 1997 Dec;20(12):1874-9.PMID: 9405910 [PubMed - indexed for MEDLINE]Related articles

    13.

    Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.

    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.

    Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.PMID: 12189441 [PubMed - indexed for MEDLINE]Related articles

    14.

    The effect of single-dose orlistat on postprandial serum glucose, insulin and glucagon-like peptide-1 levels in nondiabetic obese patients.

    Sahin M, Tanaci N, Yucel M, Tutuncu NB, Guvener N.

    Clin Endocrinol (Oxf). 2007 Sep;67(3):346-50. Epub 2007 May 24.PMID: 17524030 [PubMed - in process]Related articles

    15.

    alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.

    Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.

    Diabet Med. 2005 Apr;22(4):470-6.PMID: 15787675 [PubMed - indexed for MEDLINE]Related articles

    16.

    Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.

    J Clin Invest. 1993 Jan;91(1):301-7.PMID: 8423228 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    [Pharmacological therapy of obesity]

    Pagotto U, Vanuzzo D, Vicennati V, Pasquali R.

    G Ital Cardiol (Rome). 2008 Apr;9(4 Suppl 1):83S-93S. Italian. PMID: 18773755 [PubMed - indexed for MEDLINE]Related articles

    18.

    Orlistat augments postprandial increases in glucagon-like peptide-1 in obese type 2 diabetic patients: response to Damci et al.

    Horowitz M, Feinle-Bisset C, Jones K, Nauck M.

    Diabetes Care. 2004 Nov;27(11):2770; author reply 2771. No abstract available. PMID: 15505026 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Effect of glucagon on carbohydrate-mediated secretion of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-36 amide) (GLP-1).

    Ranganath L, Schaper F, Gama R, Morgan L, Wright J, Teale D, Marks V.

    Diabetes Metab Res Rev. 1999 Nov-Dec;15(6):390-4.PMID: 10634963 [PubMed - indexed for MEDLINE]Related articles

    20.

    Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.

    Diabetes Care. 1996 Jun;19(6):580-6.PMID: 8725855 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity